more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$148.98 USD

-3.69 (-2.42%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $148.88 -0.10 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?

by Zacks Equity Research Published on November 15,2017

Surging implied volatility makes Sarepta Therapeutics (SRPT) Stock lucrative to the option traders.

SRPTNegative Net Change

BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised

by Zacks Equity Research Published on October 27,2017

BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.

Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised

by Zacks Equity Research Published on October 26,2017

Sarepta (SRPT) beat estimates on both counts in the third quarter of 2017 on strong sales of Exondys 51. Sarepta's pipeline candidate, golodirsen, shows potential.

Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?

by Zacks Equity Research Published on October 24,2017

Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.

SRPTNegative Net Change

What's in Store for BioMarin (BMRN) This Earnings Season?

by Zacks Equity Research Published on October 23,2017

BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.

Catabasis' DMD Candidate Slows Disease Progression, Stock Up

by Zacks Equity Research Published on October 05,2017

Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.

Here's Why Sarepta Stock is Up More Than 60% So Far in 2017

by Zacks Equity Research Published on September 25,2017

Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51's strong performance. The settlement of a patent litigation also boosted the stock.

Sarepta's Golodirsen Positive in DMD Study, Shares Soar

by Zacks Equity Research Published on September 07,2017

Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.

Why Is Sarepta (SRPT) Down 9.9% Since the Last Earnings Report?

by Zacks Equity Research Published on August 22,2017

Sarepta (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SRPTNegative Net Change

What You See, and What You Get: The Neurology of Perception

by Kevin Cook Published on August 15,2017

While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.

BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates

by Zacks Equity Research Published on August 03,2017

BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.

Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why

by Madeleine Johnson Published on July 20,2017

On Thursday, shares of Sarepta Therapeutics (SRPT) are surging, up almost 24% to $42.14 per share in morning trading after the biotech company reported second-quarter revenues that blew past expectations in its earnings report yesterday after the bell.

Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View

by Zacks Equity Research Published on July 20,2017

Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.

Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

by Zacks Equity Research Published on July 19,2017

Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.

Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD

by Zacks Equity Research Published on July 13,2017

Mallinckrodt plc (MNK) announced that the FDA has granted orphan drug designation to its pipeline candidate - MNK-1411, which is being evaluated for the treatment of Duchenne muscular dystrophy (DMD).

Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017

by Zacks Equity Research Published on June 30,2017

We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.

Sarepta Appoints Ex-Allergan Executive as CEO and President

by Zacks Equity Research Published on June 29,2017

Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).

Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

by Zacks Equity Research Published on April 28,2017

Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased